Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Stress-Busting supplement? new study tests postbiotic in 50-75 year olds

NCT ID NCT07471659

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 03, 2026 · Updated 2 times

Summary

This study tests whether taking a daily postbiotic supplement called Humiome® Post LB for three months can lower stress levels in adults aged 50 to 75. About 200 participants in France will either receive the supplement or a placebo, and their stress will be measured using a standard questionnaire. The goal is to see if this simple daily addition can improve wellbeing in an older population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA: * Men and women aged between 50 and 75 years old (limits included), * Body mass index (BMI) ≥ 18.5 and \< 30 kg/m² * Presenting a level of psychological stress characterized by a PSS-10 score ≥ 14 and ≤ 26, * For women: not at risk of pregnancy (as per definitions of Appendix 13) Participants currently of childbearing potential, using an effective method of contraception. * Menopausal without hormone replacement therapy (estrogenic replacement therapy stopped since more than 3 months can be included) * Good general and mental health according to the opinion of the investigator: No relevant abnormalities from medical history nor from the medical consultation * Agreeing to maintain lifestyle habits during the study (same dietary and physical activity habits) * Able and willing to participate to the trial by complying with the protocol procedures as evidenced by a dated and signed ICF * Affiliated with a social security scheme, * With access to a health-care provider, who can be contacted by the CRO, and who reside in areas with available emergency health services, * Agreeing to be registered in the national database of subjects participating in clinical research, * Having a smartphone or personal computer compatible with the eConsult and ePRO applications. EXCLUSION CRITERIA: * Suffering from a metabolic disorder such as treated or untreated diabetes, * Suffering from thyroid dysfunction, high blood pressure or other metabolic disorders treated for less than 6 months and/or non-stabilized, * Suffering from a severe chronic disease: cancer, HIV, renal failure, hepatic or biliary disorders ongoing (except for cholecystectomy since more than two years and asymptomatic), chronic inflammatory digestive disease, arthritis or other chronic respiratory trouble (except for mild asthma under treatment), * Suffering from GI disorders found to be inconsistent with the conduct of the study by the investigator (e.g. celiac disease, Chron's disease, etc.), * With a known food allergy or intolerance or hypersensitivity to any of the trial products' ingredients, * Women who are pregnant or lactating or intend on becoming pregnant within the following six months, * Having a history or presence of a psychiatric or neurologic disease including epilepsy, cerebrovascular disturbance, traumatic brain injury, dementia, Alzheimer's Disease, clinical depression, or other clinically significant psychiatric/neurologic condition that could interfere with the interpretation of the study results in the opinion of the investigator, * Having recently experienced or currently experiencing a significant stress as per investigator's judgment (e.g. grieving, divorce, moving, etc.), * Having a condition and/or receiving a treatment that may cause immunosuppression (e.g.: under immunomodulating treatment for HIV infection, allograft, auto-immune disease or cancer, etc.) * Under treatment or dietary supplement which could significantly affect parameter(s) followed during the trial according to the investigator or stopped less than one month prior to V1, * Under treatment with one or more of the following treatments stopped less than one month prior to V1: * psychotropic medications (including antidepressants and tranquilizers), stimulant medications, and/or narcotics having an effect on stress, sleep aid medications, supplements, and/or products, including antihistamines, acid-blocking medication (e.g., proton pump inhibitor, H2 blocker), * Under treatment with an effect on the microbiome such as antibiotics stopped less than one month prior to V1, * Having a lifestyle deemed incompatible with the trial according to the Investigator as described below: * Practicing a high-level of physical activity (defined as more than 10 hours of intense physical activity a week, walking excluded), * Regularly consuming more than 2 standard drinks of alcohol daily or 14 weekly or not agreeing to keep alcohol consumption habits unchanged throughout the study, * With a significant change in dietary or physical activity habits in the 3 months prior to randomisation (no hyper or hypocaloric diet, no high-protein diet, no prolonged fasting for more than one week, no planned change in the level of sports activity in the next 3 months), * With a personal history of anorexia nervosa, bulimia, or significant eating disorders according to the Investigator, * Taking part in another clinical trial or being in the exclusion period of a previous clinical trial, * Having received, during the last 12 months, indemnities for clinical trial higher or equal to 6000 Euros, * Under legal protection (guardianship, wardship) or deprived of rights following an administrative or judicial decision, * Presenting a psychological or linguistic incapability to sign the ICF, Impossible to contact in case of emergency.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stress are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Biofortis

    RECRUITING

    Saint-Herblain, 44800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.